STRO

Sutro BiopharmaB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$40.00

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$19.00

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$11.00

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-03

AI commentary

Primary company and SEC materials are constructive on early STRO-004 activity and pipeline execution, but the evidence is immature and mixed with dose-limiting toxicity risk. The packet includes a secondary headline describing a 15% selloff on August 12, but its cause is not independently confirmed. No analyst target count, post-print estimate revision, or earnings-surprise comparison is available. No direct operating peer set is established, so confidence remains restrained [#SEC-8K-2026-08-12].

RankAlpha Sentiment Codex - 2026-09-03

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-02eventSTRO-006 clinic entryHigh impact

Management said the ITGB6-targeting ADC was on track to enter the clinic in Q3 2026, providing a near-term pipeline execution checkpoint [#SEC-8K-2026-08-12].

2026-12-02eventAstellas dual-payload program advancementHigh impact

A second dual-payload iADC program under the Astellas collaboration was expected to enter the clinic in the second half of 2026, supporting external validation but remaining execution-dependent [#SEC-8K-2026-08-12].

2026-12-02catalystSTRO-004 early-data digestionHigh impact

The August update showed multiple confirmed and ongoing unconfirmed partial responses across three tumor types, favorable tolerability, and predictable PK, but the Phase 1 study remains early and the maximum tolerated dose is not defined [#SEC-8K-2026-08-12][#PR-EARNINGS-2026-08-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-03 • Updated nightlySource: Internal modelMethodology